In an attempt to pinpoint the in vivo functions of
ever, no reduction of fat mass is observed in adiposetermed adaptive thermogenesis, also occurs in skeletal specific ablation of PPAR␦ mice (Barak et al., 2002) , muscle. While a set of uncoupling proteins (UCPs) on the indicating a complex, nonautonomous action. These mitochondrial inner membrane are the ultimate effectors data collectively implicate PPAR␦ in lipid homeostasis; for adaptive thermogenesis, they must coordinate with but which metabolic pathway it regulates in vivo and fuel oxidation, which generates the energy (electrowhether it functionally overlaps with PPAR␥ or PPAR␣ remain unclear.
In an attempt to pinpoint the in vivo functions of *Correspondence: evans@salk.edu PPAR␦, we undertook a gain-of-function approach by selectively expressing an active form of PPAR␦ in adipose tissue. The resulting transgenic mice display decreased lipid accumulation in both adipose tissue and serum. The mice are lean and are protected from obesity. Additionally, short-term treatment of obese mice with PPAR␦ agonist causes a dramatic lipid depletion in tissues. These phenotypes are consistent with an elevated energy expenditure. Indeed, we find that PPAR␦ activates an array of genes required for fatty acid combustion and uncoupling, but not that of genes involved in lipogenesis and storage, which are controlled by PPAR␥. Furthermore, PPAR␦-deficient mice fed with high-fat diet display reduced energy uncoupling and are prone to obesity. In corroboration with these in vivo findings, we demonstrate that activation of PPAR␦ stimulates ␤-oxidation and triglyceride utilization in adipocytes and myocytes. Our data suggest that PPAR␦ is a key regulator of fat burning in peripheral tissues by coordinating fatty acid oxidation and energy uncoupling.
Results

Activation of PPAR␦ in Adipose Tissue Decreases Fat Mass and Lipid Accumulation
We fused the 78 amino acid VP16 activation domain of the herpes simplex virus to the N-terminal end of PPAR␦. In cell transfection assays, this fusion protein (VP16-PPAR␦) shows potent ligand-independent transactivation on our synthetic pan-PPAR response element, but not on the response elements of other nuclear receptors (data not shown). Like wild-type PPAR␦, VP16-PPAR␦ has no effect on a reporter containing a native PPAR␥-specific response element we identified recently (Y. Barak and R.M.E., unpublished data), suggesting that VP16-PPAR␦ has no altered promoter selectivity. We expressed VP16-PPAR␦ in adipose tissue under the control of the enhancer-promoter region of the adipocyte fatty acid binding protein (aP2) gene (Ross et al., 1990) . Three transgenic founders a, b, and c were obtained, which are distinguishable from their littermates due to a marked reduction in body weight and adiposity or fatty liver ( Figure 1A and data not shown). These distinctions argue against an adipogenesis defect and raise the possibility that the fat pad in our transgenic mice may have increased fatty acid consumption, anti-PPAR␦ and anti-VP16 antibodies ( Figures 2B and  2C ). Compared to that of endogenous PPAR␦, the level thereby precluding significant storage in either liver or other organs. Founder b and c show similar reduction of VP16-PPAR␦ protein is lower in white fat (WAT), but is similar or slightly higher in brown fat (BAT). Adipocytein fat pad size ( Figure 1B and see Figure 3D ), and based on reproductive competency (normal size litters and exdifferentiation-related protein (ADRP) is a lipid droplet coating protein and its expression is induced by PPAR␦ pected ratio of transgene), a cohort was expanded from the c male.
activation (Vosper et al., 2001 ). Indeed, Northern blot analysis revealed a 3-fold increase of ADRP gene exWe estimated that there are 2-3 copies of the transgene present in the genome (Figure 2A ). The transgene pression in the brown fat of transgenic mice, confirming that the VP16-PPAR␦ is functional in vivo ( Figure 2D ). is expressed in both white fat and brown fat but is absent in other tissues, as shown by Western blot analysis with Interestingly, we did not observe a significant induction of ADRP in white fat, indicating that target gene regulamine whether the reduced fat weight and lipid accumulation occur at the expense of lipid buildup in the circulation by PPAR␦ is highly tissue or cell-type-selective.
On a standard diet, despite a daily food intake similar tion, we assayed serum lipid levels. While levels of total cholesterol remain unchanged, those of total triglyceride to that of control littermates when measured in individually housed mice ( Figure 3A) , the transgenic mice are and free fatty acid are significantly decreased ( Figure  3F ). These results, together with the lack of lipid accuabout 20% smaller in body weight at 4 months old, and this difference is increased to 35% at 12 months old mulation in liver and muscle, are consistent with our hypothesis that activation of PPAR␦ in adipose pro-( Figure 3B ). In contrast, transgenic expression of the VP16 activation domain alone in adipose tissue (aP2-motes fatty acid consumption. VP16) produces no discernable differences relative to control nontransgenic littermates in body weight, physiActivation of PPAR␦ in Adipose Protects against Obesity and Hyperlipidemia ology, or histology ( Figure 3C and data not shown). We measured the weight of various tissues normalized by In principle, enhanced fatty acid utilization should protect mice against high-fat diet induced obesity. Accordbody weight in VP16-PPAR␦ transgenic mice. There is a 40% decrease in the reproductive white fat depot ingly, we challenged 8-week-old mice with a high-fat diet containing 35% (w/w) fat for 32 days to stimulate ( Figure 3D ). This is in marked contrast to other tissues including brown fat, liver, heart, and kidney, which have weight gain. As shown in Figure 4A , weight gain is highly blunted in the transgenic mice relative to the control weights similar to wild-type and exhibit no gross abnormalities. Adipose tissues, but not other tissues, show littermates. A statistical difference is observed as early as the first two weeks of feeding. By the end of this striking morphological changes ( Figure 3E) with vehicle or GW501516 for 7 days. We then examined UCPs. All three UCPs are expressed in brown fat with UCP1 being most abundant. Activation of PPAR␦ inthe histology of brown fat and liver, since these two tissues accumulate unusual amounts of lipids in Lepr db/db duces expression of UCP1 and UCP3 in brown fat by 3.0-and 2.8-fold, respectively, but has no effect on the mice. As shown in transcriptional coactivator PGC-1␣ (Puigserver et al., gregate, our gene expression data reveal that PPAR␦ activates each of the three steps of fatty acid catabolism 1998); however, no upregulation of PGC-1␣ is found in either white fat or brown fat of the transgenic mice (data in brown fat: hydrolysis, oxidation, and uncoupling of oxidative phosphorylation. The ability of PPAR␦ activanot shown). Although the level of UCP1 induced by PPAR␦ in white fat is low relative to that in brown fat, tion to prevent high-fat-induced fatty liver raised the possibility that this might be due to an indirect effect its functional significance cannot be excluded, given the large quantity of white fat. Indeed, low levels of on fatty acid synthesis in liver. An examination of the expression levels of acetyl-CoA carboxylase 1(ACC1), transgenic UCP1 expression in white fat are sufficient to protect against obesity (Kopecky et al., 1996) . In agfatty acid synthase (FAS), and SREBP1 in the liver re-veals no obvious differences of transgenic mice and In agreement with increased glycerol release, the amount of total triglyceride in cells decreases significontrol littermates ( Figure 6C ). These results suggest cantly ( Figure 7B ). Moreover, we observed no difference that the observed phenotypes are indeed direct consein the levels of free fatty acids in the media between quences of activated metabolism in adipose tissue.
control and PPAR␦ or VP16-PPAR␦ overexpression exHaving established that PPAR␦ acts as a thermogenic periments (data not shown), suggesting that the free transcriptional factor, we reasoned that ablation of fatty acids derived from triglyceride hydrolysis are effec-PPAR␦ should constrain the oxidative response, retively burned. sulting in increased body weight gain upon energy overTo determine whether endogenous PPAR␦ promotes load. As previously reported, PPAR␦ null mice are runted fatty acid utilization and to provide direct evidence that at birth and during the first 12 months and weigh much PPAR␦ acts upon the ␤-oxidation pathway, we mealess than wild-type mice under normal chow diet. Howsured the level of ␤-oxidation in 3T3-L1 preadipocytes. ever, when placed on a high-fat diet, they gain weight Remarkably, while agonists for PPAR␣ (WY14643) or rapidly and their body weights surpass those of wild-PPAR␥ (BRL49653) have little effect, PPAR␦ agonist type mice after a 3 weeks trial (41.8 Ϯ 1.97 g versus GW501516 stimulates ␤-oxidation by 50%, demonstra-34.9 Ϯ 2.34 g, n ϭ 6, P Ͻ 0.05; Figure 6D ). In contrast, ting that activation of endogenous PPAR␦ is sufficient during this feeding period, age-matched PPAR␦ null to increase fatty acid combustion ( Figure 7C ). Basal mice under chow diet or age-matched wild-type mice ␤-oxidation is increased by overexpressing PPAR␦, and under either chow diet or high-fat diet show little weight addition of GW501516 or overexpression of VP16-changes. We also observed that PPAR␦ null mice accu-PPAR␦ results in a 2-fold increase ( Figure 7D ). In conmulate much higher amount of lipids in brown fat than trast, overexpression of PPAR␥ plus its agonist BRL49653 controls under high-fat diet (data not shown). We then has only a marginal effect on ␤-oxidation, consistent examined UCP1 expression in brown fat of both adiwith distinct functions for individual PPAR isoforms. pose-specific PPAR␦ knockout and null mice (Barak et We next investigated whether PPAR␦ can play a simial., 2002). Under normal chow diet, levels of UCP1 are lar role in fatty acid catabolism and uncoupling in skelesimilar between floxed PPAR␦ mice (controls) and floxed tal muscle. C2C12 cells were differentiated into myo-PPAR␦ mice with aP2-CRE (knockouts). Whereas UCP1 tubes and then treated with PPAR agonists. Consistent is robustly induced after 1 week high-fat feeding in conwith our observations in adipocytes, the PPAR␦ agonist trol animals, the induction is significantly compromised GW501516 significantly increases fatty acid oxidation in knockouts ( Figure 6E ). Similar decrease of UCP1 exin myotubes, with no effects found for either PPAR␣ or pression is observed in PPAR␦ null mice fed with high-PPAR␥ agonists ( Figure 7E ). Activation of ectopically fat diet ( Figure 6F ). Thus, under conditions of high-fat expressed PPAR␦ in myotubes leads to a much more diet, loss of PPAR␦ in adipose tissue or in the whole robust stimulation ( Figure 7E ). Again, activation of ecanimal results in impaired thermogenesis, partially extopically expressed PPAR␥ produces little effect. In plaining the rapid weight gain of null mice. agreement with the oxidation data, the GW501516 compound induces the expression of genes required for PPAR␦ Stimulates Fatty Acid Oxidation fatty acid oxidation and uncoupling, while little or no in Cultured Adipocytes and Myocytes, induction is observed for PPAR␣ or PPAR␥ agonists and Associates with the Thermogenic (Figure 7F ). Conversely, GW501516 treatment has no Cofactor PGC-1␣ In Vivo effects on genes for lipogenesis or fatty acid transport We asked whether the function of PPAR␦ could be reca-( Figure 7F ). These in vitro results, together with our in pitulated in vitro. In vivo studies with activated PPAR␦ vivo gene expression data, clearly demonstrate that described here and adipose-specific PPAR␦ ablation PPAR␦ controls fatty acids metabolism by promoting (Barak et al., 2002) suggest that PPAR␦ is not involved ␤-oxidation and energy uncoupling in peripheral tissues. in adipogenesis. In support of the in vivo data, we found Our results also indicate that, unlike PPAR␦, PPAR␥ no inhibitory or stimulatory effects of PPAR␦ on 3T3-and PPAR␣ have very limited thermogenic roles in both L1 adipocyte differentiation (data not shown). We next adipose and skeletal muscle. determined whether overexpression of PPAR␦ proThe thermogenic function of PPAR␦ described here motes triglyceride consumption (Figures 7A and 7B) .
is remarkably similar to that of the transcriptional coactiPreadipocytes were allowed to reach a fully differentivator PGC-1␣, raising the possibility that PGC-1␣ acts ated state with triglyceride accumulation and then inthrough PPAR␦ to promote thermogenesis. Indeed, in fected with virus expressing PPAR␦ or VP16-PPAR␦. 293 cells overexpressing PPAR␦ and PGC-1␣, coimmuWe assayed the levels of glycerol released into culture noprecipitation studies reveal a strong physical interacmedium as an indicator of triglyceride metabolism. As tion between these two proteins ( Figure 7G ). This intershown in Figure 7A Figure 7H ). In conthe medium (data not shown). We also measured total trast, the coactivator p300, the p160 family member ACTR, or the LXXLL mutant of PGC-1␣ is inactive. Fiintracellular triglyceride levels following virus infection. , 2002) ; however, the major target transcriptional pathway through which PPAR␦ in Anti-Obesity Therapies Obesity is a devastating medical and social problem it mediates this effect is not known. Our data suggest that PPAR␦ may be the unidentified factor. The fact that with increasing prevalence of potentially epidemic proportions. Manipulation of adaptive thermogenesis has these two proteins both activate thermogenesis in the same tissues by regulating common target genes lead long been pursued to treat obesity (Spiegelman and Flier, 2001 ). For example, thyroid hormones stimulate us to speculate that PPAR␦ may employ PGC-1␣ as its predominant coactivator in this pathway. This idea is thermogenesis by an uncertain mechanism and can promote weight loss, but they also produce side effects further enforced by their induction of UCP genes in a similar cell type-selective pattern. In white fat, both such as loss of lean body mass and cardiac toxicity. The identification of players in this pathway could create PGC-1␣ and PPAR␦ induce UCP1 but not UCP2 or UCP3, whereas in muscle both induce UCP2 and UCP3, pharmacologic opportunities. Even though PGC-1␣ and the uncoupling proteins are potential therapeutic tarbut not UCP1. We find that PGC-1␣ is a potent coactivator for PPAR␦ in muscle cells and, importantly, these gets, PPAR␦ as a nuclear receptor, represents a bona vine calf serum and differentiated using standard protocols with 0.5 used as controls throughout the study. As an additional control, we mM 3-isobutyl-1-methylxanthine, 0.25 M dexamethasone, and 5 also generated aP2-VP16 transgenic mice, which behave identically g/ml insulin as inducers ( 
